Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.O)

ACRX.O on Consolidated Issue listed on NASDAQ Global Market

3.25USD
19 Sep 2017
Change (% chg)

$0.05 (+1.56%)
Prev Close
$3.20
Open
$3.25
Day's High
$3.30
Day's Low
$3.20
Volume
712,300
Avg. Vol
1,023,715
52-wk High
$4.08
52-wk Low
$1.95

Select another date:

Wed, Aug 23 2017

BRIEF-Acelrx pharmaceuticals says co entered into 2nd amendment with Patheon Pharma

* Acelrx Pharmaceuticals - on August 22, co entered second amendment to manufacturing services deal effective as of august 4, 2017, with Patheon Pharma

BRIEF-Acelrx Pharmaceuticals Q2 loss per share $0.29

* Acelrx Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-AcelRx Pharmaceuticals reports successful outcome of Zalviso phase 3 IAP312 study on device functionality

* Acelrx Pharmaceuticals reports successful outcome of zalviso phase 3 IAP312 study on device functionality

BRIEF-Acelrx Pharmaceuticals appoints Raffi Asadorian CFO

* Acelrx Pharmaceuticals appoints Raffi Asadorian as chief financial officer

BRIEF-Acelrx Pharmaceuticals updates on notification from U.S. FDA

* U.S. FDA notified co that it no longer plans to hold an advisory committee meeting in connection with its review of NDA for Dsuvia

BRIEF-Acelrx Pharmaceuticals files for mixed shelf of up to $150 mln

* Acelrx Pharmaceuticals Inc files for mixed shelf of up to $150.0 million - sec filing Source text - http://bit.ly/2ruEt7F Further company coverage:

BRIEF-Acelrx Pharmaceuticals CFO Timothy Morris resigns

* Acelrx Pharmaceuticals - on June 2, CFO Timothy E. Morris notified co of his resignation from all positions with co effective immediately - SEC filing

BRIEF-AcelRx Pharmaceuticals reports Q1 total revenue $3.1 million

* AcelRx Pharmaceuticals reports first quarter 2017 financial results and provides corporate update

BRIEF-AcelRx Pharma says DSUVIA resulted in 3-point reduction in pain intensity within 60 minutes of administration

* AcelRx Pharmaceuticals presenting comprehensive DSUVIA clinical trial results at ASRA's annual regional anesthesiology and acute pain medicine meeting

BRIEF-European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil

* European Medicines Agency begins evaluation of marketing application for sublingual Sufentanil 30 mcg tablet (ARX-04) for moderate-to-severe acute pain

Select another date: